Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:10 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 121,318 matching trials from the live ClinicalTrials.gov search.
Filters: Completed Clear all
Completed Phase 4 Interventional Results available

Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes

NCT01409239
View directory record Official record
Conditions
Type 2 Diabetes, Inpatient
Interventions
Intravenous insulin, Subcutaneous Insulin
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 3 Interventional Results available

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

NCT01810939
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Hyperkalemia (HK)
Interventions
Patiromer, Placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
14
States / cities
Azusa, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Nov 3, 2026, 7:10 AM EST
Completed No phase listed Observational

Understanding the Differences in the Management of Patients With Arthritis of the Knee or Hip

NCT00105677
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Degenerative, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 79 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 2 Interventional

Effects of Walking Analysis on Surgical Outcomes

NCT00114075
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Surgery with gait analysis report, Surgery without gait analysis report
Procedure
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
3 Years to 18 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Nov 3, 2026, 7:10 AM EST
Completed Not applicable Interventional

Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors

NCT03953157
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Arthralgia, Postmenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Dietary Intervention, Exercise Intervention, Questionnaire Administration
Dietary Supplement · Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Nov 3, 2026, 7:10 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Radical Openness for Adolescents Pilot

NCT05913557
View directory record Official record
Conditions
Anorexia Nervosa, Obsessive-Compulsive Disorder, Social Phobia, Depression, Anxiety
Interventions
Radically Open Dialectical Behavior Therapy (RO DBT)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 3, 2026, 7:10 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator

NCT01679301
View directory record Official record
Conditions
Lung Disease
Interventions
Pulse Dose (Sleep Mode), Continuous Dose
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 3 Interventional

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

NCT00241501
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 1 Interventional

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

NCT02395601
View directory record Official record
Conditions
B-Cell Lymphoma
Interventions
CPI-1205
Drug
Lead sponsor
Constellation Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Lafayette, Indiana • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Nov 3, 2026, 7:10 AM EST
Completed Not applicable Interventional

Pilot Testing PICTURE-THIS

NCT06086301
View directory record Official record
Conditions
Post-intensive Care Syndrome, Transitional Care, Critical Care, Health Services
Interventions
PICTURE-THIS, Enhanced Usual Care, Run-In Phase
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 3 Interventional Results available

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

NCT01087801
View directory record Official record
Conditions
Pancreatic Disease
Interventions
ChiRhoStim, Placebo
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Nov 3, 2026, 7:10 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Variability of the Ventilatory Response to Duffin's Rebreathing Procedure

NCT05168501
View directory record Official record
Conditions
Ventilation, Reproducibility, Physiology
Interventions
Rebreathing procedure
Other
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Nov 3, 2026, 7:10 AM EST
Completed Not applicable Interventional Results available

Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

NCT04007601
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 39 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 1 Interventional

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)

NCT01494701
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 14 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Nov 3, 2026, 7:10 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery

NCT05583981
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Interview
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 3 Interventional Results available

Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne

NCT00776919
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin / benzoyl peroxide gel, clindamycin gel, BPO gel, vehicle gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
San Diego, California • Santa Monica, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Nov 3, 2026, 7:10 AM EST
Completed No phase listed Observational

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

NCT01339481
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Anniston, Alabama • Palm Harbor, Florida • Wheaton, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 2 Interventional Results available

Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients

NCT02015481
View directory record Official record
Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
Cabaletta
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

NCT01128530
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections
Interventions
JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cilostazol 50 mg Tablets Under Fasting Conditions

NCT00839930
View directory record Official record
Conditions
Healthy
Interventions
Cilostazol 50 mg Tablets, Pletal®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

NCT01792830
View directory record Official record
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 1Phase 2 Interventional

Barriers to Treatment in Obese Adolescents

NCT00167830
View directory record Official record
Conditions
Obesity
Interventions
Motivational Interviewing, Strength and Cardiovascular Conditioning, Food selection and portion control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
11 Years to 18 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 2 Interventional Results available

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

NCT02029430
View directory record Official record
Conditions
Kaposi's Sarcoma, HIV Positive, AIDS
Interventions
50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Nov 3, 2026, 7:10 AM EST
Completed Phase 2 Interventional

Materna Prep Study Phase II

NCT06126328
View directory record Official record
Conditions
Vaginal Delivery, Pelvic Organ Prolapse
Interventions
Materna Prep Device
Device
Lead sponsor
Materna Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Mountain View, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Nov 3, 2026, 7:10 AM EST